Nektar Therapeutics (NKTR) Capital Leases (2010 - 2017)

Nektar Therapeutics has reported Capital Leases for 8 years, with the latest figure at $3.0 million in Q3 2017.

• For the quarter ending Q3 2017, Capital Leases rose 39.99% year-over-year to $3.0 million; the trailing twelve-month figure through Sep 2017 stood at $3.0 million (up 39.99% YoY), and the FY2016 full-year result was $2.2 million, up 107.18% from the prior year.
• Capital Leases for Q3 2017 stood at $3.0 million, up from $1.1 million in the prior quarter.
• The five-year high for Capital Leases was $10.8 million in Q1 2013, with the low at $1.1 million in Q2 2017.
• Average Capital Leases over 5 years is $5.4 million, with a median of $5.3 million recorded in 2014.
• Year-over-year, Capital Leases surged 107.18% in 2016 and plunged 80.14% in 2017.
• Tracing NKTR's Capital Leases over 5 years: stood at $8.0 million in 2013, then slumped by 48.58% to $4.1 million in 2014, then sank by 74.08% to $1.1 million in 2015, then surged by 107.18% to $2.2 million in 2016, then surged by 34.95% to $3.0 million in 2017.
• The last three Capital Leases figures came in at $3.0 million (Q3 2017), $1.1 million (Q2 2017), and $1.6 million (Q1 2017), per Business Quant data.

Peer Comparison